GeneDx Holdings Corp. (NASDAQ:WGS) CFO Sells $286,124.00 in Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 3,728 shares of the company’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $76.75, for a total value of $286,124.00. Following the sale, the chief financial officer now owns 28,200 shares of the company’s stock, valued at $2,164,350. The trade was a 11.68 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Kevin Feeley also recently made the following trade(s):

• On Monday, December 9th, Kevin Feeley sold 1,137 shares of GeneDx stock. The stock was sold at an average price of $76.37, for a total value of $86,832.69.
• On Monday, December 2nd, Kevin Feeley sold 263 shares of GeneDx stock. The shares were sold at an average price of $78.39, for a total value of $20,616.57.
• On Thursday, November 21st, Kevin Feeley sold 12,019 shares of GeneDx stock. The stock was sold at an average price of $73.76, for a total value of $886,521.44.
• On Tuesday, October 29th, Kevin Feeley sold 274 shares of GeneDx stock. The shares were sold at an average price of $66.60, for a total transaction of $18,248.40.

GeneDx Stock Up 2.8 %

Shares of NASDAQ WGS opened at $77.40 on Friday. GeneDx Holdings Corp. has a 52-week low of $2.47 and a 52-week high of $89.11. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40. The company’s 50 day moving average price is $72.46 and its 200-day moving average price is $47.35. The company has a market capitalization of $2.13 billion, a P/E ratio of -24.89 and a beta of 2.03.

GeneDx (NASDAQ:WGS) last issued its earnings results on Tuesday, October 29th. The company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.25. GeneDx had a negative return on equity of 13.35% and a negative net margin of 31.25%. The business had revenue of $76.90 million during the quarter, compared to the consensus estimate of $64.98 million. During the same period in the previous year, the company posted ($0.82) earnings per share. The firm’s revenue for the quarter was up 44.3% on a year-over-year basis. Equities analysts forecast that GeneDx Holdings Corp. will post -0.24 earnings per share for the current year.

Hedge Funds Weigh In On GeneDx

Institutional investors have recently made changes to their positions in the stock. Acadian Asset Management LLC bought a new position in shares of GeneDx in the 2nd quarter worth $34,000. nVerses Capital LLC acquired a new position in shares of GeneDx during the second quarter valued at about $50,000. CWM LLC bought a new stake in shares of GeneDx during the third quarter worth about $89,000. SG Americas Securities LLC bought a new stake in shares of GeneDx during the third quarter worth about $198,000. Finally, Point72 DIFC Ltd bought a new position in GeneDx in the 3rd quarter valued at about $220,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on WGS. Wells Fargo & Company increased their price objective on shares of GeneDx from $34.00 to $75.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 30th. Craig Hallum raised their price objective on GeneDx from $70.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. Finally, The Goldman Sachs Group boosted their target price on shares of GeneDx from $54.00 to $70.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $59.33.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.